| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Molecular Biology Laboratory, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Cyclin B1 is a key molecule for G2-M-phase transition during
the cell cycle and is overexpressed in various tumor types. However,
the expression status of cyclin B1 in lung cancer and its clinical
significance remain unknown. We used immunohistochemistry studies to
examine the expression of cyclin B1 in 77 non-small cell lung cancer
specimens from patients with histological stage I disease. All of the
patients underwent curative surgical treatment. The median length of
follow-up care is 8.2 years. High-level cyclin B1 expression (a cyclin
B1 labeling index 
15%) was observed in 17 of the 77
(22%) tumors. Patients whose tumors expressed a high level of cyclin
B1 had a significantly shorter survival time than patients whose tumors
expressed a low level of cyclin B1 (P = 0.02, log-rank test). Interestingly, overexpression of cyclin B1 was
more frequently observed in tumors with squamous cell histology than in
tumors with other histological cell types (P = 0.01, Fisher’s exact test). A subgroup analysis revealed that
cyclin B1 overexpression seems to be an adverse prognostic factor only
in patients with squamous cell carcinoma (SCC) of the lung
(P = 0.02, log-rank test). Our data
indicate that cyclin B1 may be dysregulated in non-small cell lung
cancer, particularly in the SCC subtype, and that a high level of
cyclin B1 expression may be a prognostic marker for patients with
early-stage SCC of the lung.
This article has been cited by other articles:
|
|
 |
|
  Y. Song, C. Zhao, L. Dong, M. Fu, L. Xue, Z. Huang, T. Tong, Z. Zhou, A. Chen, Z. Yang, et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis Carcinogenesis, February 1, 2008; 29(2): 307 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Perez de Castro, G. de Carcer, and M. Malumbres A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy Carcinogenesis, May 1, 2007; 28(5): 899 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Gomez, A. de las Pozas, T. Reiner, K. Burnstein, and C. Perez-Stable Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy Mol. Cancer Ther., May 1, 2007; 6(5): 1534 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Park, G.-R. Yu, W.-H. Kim, W.-S. Moon, J.-H. Kim, and D.-G. Kim NF-Y-Dependent Cyclin B2 Expression in Colorectal Adenocarcinoma Clin. Cancer Res., February 1, 2007; 13(3): 858 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-Q Zhu, W Shih, C-H Ling, and M-S Tsao Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Payton, G. Chung, P. Yakowec, A. Wong, D. Powers, L. Xiong, N. Zhang, J. Leal, T. L. Bush, V. Santora, et al. Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors. Cancer Res., April 15, 2006; 66(8): 4299 - 4308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. EGLOFF, J. WEISSFELD, S. R. LAND, and O. J. FINN Evaluation of Anticyclin B1 Serum Antibody as a Diagnostic and Prognostic Biomarker for Lung Cancer Ann. N.Y. Acad. Sci., December 1, 2005; 1062(1): 29 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chen, M. S. Bhojani, A. C. Heaford, D. C. Chang, B. Laxman, D. G. Thomas, L. B. Griffin, J. Yu, J. M. Coppola, T. J. Giordano, et al. Phosphorylated FADD induces NF-{kappa}B, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas PNAS, August 30, 2005; 102(35): 12507 - 12512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sasayama, T. Marumoto, N. Kunitoku, D. Zhang, N. Tamaki, E. Kohmura, H. Saya, and T. Hirota Over-expression of Aurora-A targets cytoplasmic polyadenylation element binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1 Genes Cells, July 1, 2005; 10(7): 627 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Ji, J. Crest, and G. Schubiger Genetic interactions between Cdk1-CyclinB and the Separase complex in Drosophila Development, April 15, 2005; 132(8): 1875 - 1884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Suzuki, D. F. Graziano, J. McKolanis, and O. J. Finn T Cell-Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease Clin. Cancer Res., February 15, 2005; 11(4): 1521 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ren, X. Tang, J. J. Lee, L. Feng, A. D. Everett, W. K. Hong, F. R. Khuri, and L. Mao Expression of Hepatoma-Derived Growth Factor Is a Strong Prognostic Predictor for Patients With Early-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., August 15, 2004; 22(16): 3230 - 3237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Borczuk, L. Shah, G. D. N. Pearson, K. L. Walter, L. Wang, J. H. M. Austin, R. A. Friedman, and C. A. Powell Molecular Signatures in Biopsy Specimens of Lung Cancer Am. J. Respir. Crit. Care Med., July 15, 2004; 170(2): 167 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Tsao, E. S. Kim, and W. K. Hong Chemoprevention of Cancer CA Cancer J Clin, May 1, 2004; 54(3): 150 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yoshida, S. Tanaka, A. Mogi, Y. Shitara, and H. Kuwano The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer Ann. Onc., February 1, 2004; 15(2): 252 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Finn Premalignant Lesions as Targets for Cancer Vaccines J. Exp. Med., December 1, 2003; 198(11): 1623 - 1626. [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Soria, C. Moon, B. L. Kemp, D. D. Liu, L. Feng, X. Tang, Y.-S. Chang, L. Mao, and F. R. Khuri Lack of Interleukin-10 Expression Could Predict Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1785 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. S. Chang, L. Wang, D. Liu, L. Mao, W. K. Hong, F. R. Khuri, and H.-Y. Lee Correlation between Insulin-like Growth Factor-binding Protein-3 Promoter Methylation and Prognosis of Patients with Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., December 1, 2002; 8(12): 3669 - 3675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Marchetti, N. Tinari, F. Buttitta, A. Chella, C. A. Angeletti, R. Sacco, F. Mucilli, A. Ullrich, and S. Iacobelli Expression of 90K (Mac-2 BP) Correlates with Distant Metastasis and Predicts Survival in Stage I Non-Small Cell Lung Cancer Patients Cancer Res., May 1, 2002; 62(9): 2535 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nozoe, D. Korenaga, A. Kabashima, T. Ohga, H. Saeki, and K. Sugimachi Significance of Cyclin B1 Expression as an Independent Prognostic Indicator of Patients with Squamous Cell Carcinoma of the Esophagus Clin. Cancer Res., March 1, 2002; 8(3): 817 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kao, J. A. Marto, T. K. Hoffmann, J. Shabanowitz, S. D. Finkelstein, T. L. Whiteside, D. F. Hunt, and O. J. Finn Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells J. Exp. Med., November 5, 2001; 194(9): 1313 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Hassan, A. K. El-Naggar, J.-C. Soria, D. Liu, W. K. Hong, and L. Mao Clinical Significance of Cyclin B1 Protein Expression in Squamous Cell Carcinoma of the Tongue Clin. Cancer Res., August 1, 2001; 7(8): 2458 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Ferreira, P. van der Valk, S. W. Span, I. Ludwig, E. F. Smit, F. A. E. Kruyt, H. M. Pinedo, H. van Tinteren, and G. Giaccone Expression of X-linked Inhibitor of Apoptosis as a Novel Prognostic Marker in Radically Resected Non-Small Cell Lung Cancer Patients Clin. Cancer Res., August 1, 2001; 7(8): 2468 - 2474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Brognard, A. S. Clark, Y. Ni, and P. A. Dennis Akt/Protein Kinase B Is Constitutively Active in Non-Small Cell Lung Cancer Cells and Promotes Cellular Survival and Resistance to Chemotherapy and Radiation Cancer Res., May 1, 2001; 61(10): 3986 - 3997. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
